Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice

Marcio O. Lasaro, Marina Sazanovich, Wynetta Giles-Davis, Paulus Mrass, Ralph M. Bunte, Duane A. Sewell, S. Farzana Hussain, Yang Xin Fu, Wolfgang Weninger, Yvonne Paterson, Hildegund C J Ertl

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Vaccines that aim to expand tumor-specific CD8 T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models. Using a system that more faithfully mimics a progressing cancer and its immunoinhibitory microenvironment, we here show that in transgenic mice, which gradually develop adenocarcinomas due to expression of HPV-16 E7 within their thyroid, a highly immunogenic vaccine expressing E7 only induces low E7-specific CD8 T-cell responses, which fail to affect the size of the tumors. In contrast, the same type of vaccine expressing E7 fused to herpes simplex virus (HSV)-1 glycoprotein D (gD), an antagonist of the coinhibitory B-and T-lymphocyte attenuator (BTLA)/CD160-herpes virus entry mediator (HVEM) pathways, stimulates potent E7-specific CD8 T-cell responses, which can be augmented by repeated vaccination, resulting in initial regression of even large tumor masses in all mice with sustained regression in more than half of them. These results indicate that active immunization concomitantly with blockade of the immunoinhibitory HVEM-BTLA/CD160 pathways through HSV-1 gD may result in sustained tumor regression.

Original languageEnglish (US)
Pages (from-to)1727-1736
Number of pages10
JournalMolecular Therapy
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Active Immunotherapy
T-Lymphocytes
Neoplasms
Virus Internalization
Vaccines
Vaccination
Human papillomavirus 16
Transgenic Mice
Thyroid Gland
Adenocarcinoma

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Lasaro, M. O., Sazanovich, M., Giles-Davis, W., Mrass, P., Bunte, R. M., Sewell, D. A., ... Ertl, H. C. J. (2011). Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Molecular Therapy, 19(9), 1727-1736. https://doi.org/10.1038/mt.2011.88

Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. / Lasaro, Marcio O.; Sazanovich, Marina; Giles-Davis, Wynetta; Mrass, Paulus; Bunte, Ralph M.; Sewell, Duane A.; Hussain, S. Farzana; Fu, Yang Xin; Weninger, Wolfgang; Paterson, Yvonne; Ertl, Hildegund C J.

In: Molecular Therapy, Vol. 19, No. 9, 01.09.2011, p. 1727-1736.

Research output: Contribution to journalArticle

Lasaro, MO, Sazanovich, M, Giles-Davis, W, Mrass, P, Bunte, RM, Sewell, DA, Hussain, SF, Fu, YX, Weninger, W, Paterson, Y & Ertl, HCJ 2011, 'Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice', Molecular Therapy, vol. 19, no. 9, pp. 1727-1736. https://doi.org/10.1038/mt.2011.88
Lasaro, Marcio O. ; Sazanovich, Marina ; Giles-Davis, Wynetta ; Mrass, Paulus ; Bunte, Ralph M. ; Sewell, Duane A. ; Hussain, S. Farzana ; Fu, Yang Xin ; Weninger, Wolfgang ; Paterson, Yvonne ; Ertl, Hildegund C J. / Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. In: Molecular Therapy. 2011 ; Vol. 19, No. 9. pp. 1727-1736.
@article{2a7012a9542448f68ad65a0584f8eedb,
title = "Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice",
abstract = "Vaccines that aim to expand tumor-specific CD8 T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models. Using a system that more faithfully mimics a progressing cancer and its immunoinhibitory microenvironment, we here show that in transgenic mice, which gradually develop adenocarcinomas due to expression of HPV-16 E7 within their thyroid, a highly immunogenic vaccine expressing E7 only induces low E7-specific CD8 T-cell responses, which fail to affect the size of the tumors. In contrast, the same type of vaccine expressing E7 fused to herpes simplex virus (HSV)-1 glycoprotein D (gD), an antagonist of the coinhibitory B-and T-lymphocyte attenuator (BTLA)/CD160-herpes virus entry mediator (HVEM) pathways, stimulates potent E7-specific CD8 T-cell responses, which can be augmented by repeated vaccination, resulting in initial regression of even large tumor masses in all mice with sustained regression in more than half of them. These results indicate that active immunization concomitantly with blockade of the immunoinhibitory HVEM-BTLA/CD160 pathways through HSV-1 gD may result in sustained tumor regression.",
author = "Lasaro, {Marcio O.} and Marina Sazanovich and Wynetta Giles-Davis and Paulus Mrass and Bunte, {Ralph M.} and Sewell, {Duane A.} and Hussain, {S. Farzana} and Fu, {Yang Xin} and Wolfgang Weninger and Yvonne Paterson and Ertl, {Hildegund C J}",
year = "2011",
month = "9",
day = "1",
doi = "10.1038/mt.2011.88",
language = "English (US)",
volume = "19",
pages = "1727--1736",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice

AU - Lasaro, Marcio O.

AU - Sazanovich, Marina

AU - Giles-Davis, Wynetta

AU - Mrass, Paulus

AU - Bunte, Ralph M.

AU - Sewell, Duane A.

AU - Hussain, S. Farzana

AU - Fu, Yang Xin

AU - Weninger, Wolfgang

AU - Paterson, Yvonne

AU - Ertl, Hildegund C J

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Vaccines that aim to expand tumor-specific CD8 T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models. Using a system that more faithfully mimics a progressing cancer and its immunoinhibitory microenvironment, we here show that in transgenic mice, which gradually develop adenocarcinomas due to expression of HPV-16 E7 within their thyroid, a highly immunogenic vaccine expressing E7 only induces low E7-specific CD8 T-cell responses, which fail to affect the size of the tumors. In contrast, the same type of vaccine expressing E7 fused to herpes simplex virus (HSV)-1 glycoprotein D (gD), an antagonist of the coinhibitory B-and T-lymphocyte attenuator (BTLA)/CD160-herpes virus entry mediator (HVEM) pathways, stimulates potent E7-specific CD8 T-cell responses, which can be augmented by repeated vaccination, resulting in initial regression of even large tumor masses in all mice with sustained regression in more than half of them. These results indicate that active immunization concomitantly with blockade of the immunoinhibitory HVEM-BTLA/CD160 pathways through HSV-1 gD may result in sustained tumor regression.

AB - Vaccines that aim to expand tumor-specific CD8 T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models. Using a system that more faithfully mimics a progressing cancer and its immunoinhibitory microenvironment, we here show that in transgenic mice, which gradually develop adenocarcinomas due to expression of HPV-16 E7 within their thyroid, a highly immunogenic vaccine expressing E7 only induces low E7-specific CD8 T-cell responses, which fail to affect the size of the tumors. In contrast, the same type of vaccine expressing E7 fused to herpes simplex virus (HSV)-1 glycoprotein D (gD), an antagonist of the coinhibitory B-and T-lymphocyte attenuator (BTLA)/CD160-herpes virus entry mediator (HVEM) pathways, stimulates potent E7-specific CD8 T-cell responses, which can be augmented by repeated vaccination, resulting in initial regression of even large tumor masses in all mice with sustained regression in more than half of them. These results indicate that active immunization concomitantly with blockade of the immunoinhibitory HVEM-BTLA/CD160 pathways through HSV-1 gD may result in sustained tumor regression.

UR - http://www.scopus.com/inward/record.url?scp=80052414652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052414652&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.88

DO - 10.1038/mt.2011.88

M3 - Article

VL - 19

SP - 1727

EP - 1736

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 9

ER -